Kite, a Gilead Company, has agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite’s expertise in cell therapy by incorporating Interius’ integrating in vivo platform. This approach enables the generation of CAR T-cells directly within the patient’s body and may offer a more durable and long-lasting therapeutic effect by inserting DNA into the patient’s genome. Unli...